NSE ScannerPharmaceuticals · Pharmaceuticals: Other · NSE: INFLUX · data 2026-10-31
Influx Healthtech Limited
In plain words
Price: 16.0% below its 52-week high of ₹315.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹147 cr |
| Net profit (last 12 months) | ₹21 cr |
| Sales growth, 3 years (yearly) | 24.5% |
| Profit growth, 3 years (yearly) | 41.9% |
At a glance
P/E 28.3, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 30.0%, ROCE 38.0%, operating margin 17.8%: how much profit it earns on the money it uses.
Debt/equity —, Profit growth 41.9% and sales growth 24.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (30.0%).
- Profit grew 41.9% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
What is Influx Healthtech Limited's P/E ratio?
About 28.3, based on the last 12 months' earnings and a price of ₹264.5 (data 2026-10-31).
What is the 52-week high and low of Influx Healthtech Limited?
The 52-week high is ₹315 and the 52-week low is ₹170.75.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Influx Healthtech Limited | ₹264.5 | ₹612 cr | 28.3 | — | 30% | 38% | — | +48.4% |
| Amrutanjan Health Care Limited | ₹496.65 | ₹1,452 cr | 26.6 | — | 16.6% | 17.9% | 0 | -33.0% |
| Shri Ahimsa Naturals Limited | ₹399.9 | ₹952 cr | 32.1 | 4.8 | 16.7% | 18.4% | 0.1 | +55.0% |
| Lyka Labs Limited | ₹76.6 | ₹278 cr | — | — | -10.2% | -9.9% | 0.53 | -20.6% |
| Sat Kartar Life Limited | ₹130 | ₹205 cr | 10.7 | 2.4 | 28.7% | 34.8% | 0.04 | -28.2% |
| Natural Capsules Limited | ₹138.06 | ₹142 cr | — | — | -7.5% | -6.4% | 0.52 | -33.0% |
Compare INFLUX with AMRUTANJAN in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open INFLUX in NSE Scanner →